All In Biotech

Free tool

FAERS Monitor: Agrylin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020333 or its brand name (Agrylin, Anagrelide Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,175

Serious

946

81% of reports

Hospitalization

456

Death reported

128

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use82
  • anaemia63
  • platelet count increased60
  • cerebral infarction51
  • headache46
  • fatigue45
  • diarrhoea42
  • dizziness41
  • myelofibrosis41
  • haemoglobin decreased38
  • nausea36
  • asthenia34
  • hypertension34
  • palpitations33
  • renal failure33

Reports by year received

View as table
YearReports
200433
200542
200632
200722
200831
200918
201012
201158
201255
201317
201417
201534
201642
201772
201882
2019105
202087
202180
202267
2023100
202465
202566
202638

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,984 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelofibrosisSignal41246.0181.79,631
platelet count increasedSignal6082.864.64,746
cerebral infarctionSignal5137.428.61,771
haemoglobin decreasedSignal386.64.8177
anaemiaSignal635.94.7255
palpitationsSignal335.03.6104
renal failureSignal334.43.285
hypertensionSignal342.92.140
off label use821.71.423
asthenia341.61.28
dizziness411.51.16
headache461.31.03
diarrhoea421.20.91
fatigue451.00.80
nausea360.80.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.